Lurie Cancer Center Support Grant Renewed

Publication
Article
OncologyONCOLOGY Vol 11 No 2
Volume 11
Issue 2

Steven T. Rosen, MD, FACP, director of the Robert H. Lurie Cancer Center of Northwestern University, announced that the Center has been awarded a 4-year competitive renewal of its Cancer Center Support Grant (CCSG) from the National

Steven T. Rosen, MD, FACP, director of the Robert H. Lurie Cancer Centerof Northwestern University, announced that the Center has been awardeda 4-year competitive renewal of its Cancer Center Support Grant (CCSG)from the National Cancer Institute. The grant award of $1.47 million peryear supports the cancer research infrastructure of the Lurie Cancer Center.

The Robert H. Lurie Cancer Center of Northwestern University, a NationalCancer Institute-designated clinical cancer center, is the focus of cancerresearch, education, and patient care at Northwestern University. The LurieCancer Center coordinates clinical research and cancer patient care programsat the teaching affiliates of the Northwestern University Medical School,and, through the Northwestern Healthcare Network, is associated with thefollowing hospitals in the Chicago area: Children's Memorial Medical Center,Evanston and Glenbrook Hospitals, Highland Park Hospital, Ingalls HealthSystem, Northwest Community Healthcare, Northwestern Memorial Hospital,Silver Cross Hospital, and Swedish Covenant Hospital.

Recent Videos
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
2 experts are featured in this series.
2 experts are featured in this series.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
2 experts are featured in this series.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Related Content